InflaRx N.V. (IFRX) – What Are Brokerages Saying About This Stock?

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given an average recommendation of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.43.

A number of research analysts recently commented on IFRX shares. Cantor Fitzgerald boosted their price target on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, September 21st. Needham & Company LLC began coverage on shares of InflaRx in a research note on Monday, September 14th. They set a “buy” rating and a $8.00 price objective on the stock. Finally, Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $1.32 on Tuesday. The stock has a market capitalization of $194.53 million, a PE ratio of -2.28 and a beta of 2.59. The business has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $1.89. InflaRx has a fifty-two week low of $0.80 and a fifty-two week high of $2.95.

InflaRx (NASDAQ:IFRX) last released its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). On average, equities analysts expect that InflaRx will post -0.31 EPS for the current year.

Institutional Trading of InflaRx

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new stake in shares of InflaRx during the 2nd quarter worth approximately $25,000. AXQ Capital LP acquired a new position in InflaRx during the second quarter valued at approximately $41,000. ADAR1 Capital Management LLC acquired a new position in InflaRx during the first quarter valued at approximately $142,000. SteelPeak Wealth LLC acquired a new position in InflaRx during the third quarter valued at approximately $419,000. Finally, DCF Advisers LLC bought a new stake in InflaRx during the second quarter worth $512,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for severe and life-threatening inflammatory diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune system that can contribute to tissue damage when excessively activated.

InflaRx’s lead product is vilobelimab, a monoclonal antibody designed to selectively block the complement protein C5a while preserving other components of the immune response.